These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31092874)

  • 1. Degradation of D-2-hydroxyglutarate in the presence of isocitrate dehydrogenase mutations.
    Berger RS; Ellmann L; Reinders J; Kreutz M; Stempfl T; Oefner PJ; Dettmer K
    Sci Rep; 2019 May; 9(1):7436. PubMed ID: 31092874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.
    Fathi AT; Nahed BV; Wander SA; Iafrate AJ; Borger DR; Hu R; Thabet A; Cahill DP; Perry AM; Joseph CP; Muzikansky A; Chi AS
    Oncologist; 2016 Feb; 21(2):214-9. PubMed ID: 26834160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.
    Pope WB; Prins RM; Albert Thomas M; Nagarajan R; Yen KE; Bittinger MA; Salamon N; Chou AP; Yong WH; Soto H; Wilson N; Driggers E; Jang HG; Su SM; Schenkein DP; Lai A; Cloughesy TF; Kornblum HI; Wu H; Fantin VR; Liau LM
    J Neurooncol; 2012 Mar; 107(1):197-205. PubMed ID: 22015945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.
    Ward PS; Cross JR; Lu C; Weigert O; Abel-Wahab O; Levine RL; Weinstock DM; Sharp KA; Thompson CB
    Oncogene; 2012 May; 31(19):2491-8. PubMed ID: 21996744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.
    Wen H; Cho HR; Yun T; Kim H; Park CK; Lee SH; Choi SH; Park S
    J Neurochem; 2015 Jan; 132(2):183-93. PubMed ID: 25251602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.
    Suijker J; Oosting J; Koornneef A; Struys EA; Salomons GS; Schaap FG; Waaijer CJ; Wijers-Koster PM; Briaire-de Bruijn IH; Haazen L; Riester SM; Dudakovic A; Danen E; Cleton-Jansen AM; van Wijnen AJ; Bovée JV
    Oncotarget; 2015 May; 6(14):12505-19. PubMed ID: 25895133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D-2-Hydroxyglutarate in Glioma Biology.
    Chou FJ; Liu Y; Lang F; Yang C
    Cells; 2021 Sep; 10(9):. PubMed ID: 34571995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid detection of mutation in isocitrate dehydrogenase 1 and 2 genes using mass spectrometry.
    Kanamori M; Maekawa M; Shibahara I; Saito R; Chonan M; Shimada M; Sonoda Y; Kumabe T; Watanabe M; Mano N; Tominaga T
    Brain Tumor Pathol; 2018 Apr; 35(2):90-96. PubMed ID: 29671246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma.
    Bhavya B; Anand CR; Madhusoodanan UK; Rajalakshmi P; Krishnakumar K; Easwer HV; Deepti AN; Gopala S
    Cell Mol Neurobiol; 2020 Jan; 40(1):53-63. PubMed ID: 31485826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma.
    Pusch S; Schweizer L; Beck AC; Lehmler JM; Weissert S; Balss J; Miller AK; von Deimling A
    Acta Neuropathol Commun; 2014 Feb; 2():19. PubMed ID: 24529257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma.
    Mohammad N; Wong D; Lum A; Lin J; Ho J; Lee CH; Yip S
    Histopathology; 2020 Apr; 76(5):722-730. PubMed ID: 31609487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond Isocitrate Dehydrogenase Mutations: Emerging Mechanisms for the Accumulation of the Oncometabolite 2-Hydroxyglutarate.
    Peng S; Chen H; Chen L; Yang G; Liu J; Cheng X; Tang Y
    Chem Res Toxicol; 2022 Feb; 35(2):115-124. PubMed ID: 35018778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.
    Jin G; Reitman ZJ; Duncan CG; Spasojevic I; Gooden DM; Rasheed BA; Yang R; Lopez GY; He Y; McLendon RE; Bigner DD; Yan H
    Cancer Res; 2013 Jan; 73(2):496-501. PubMed ID: 23204232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
    Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
    PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting isocitrate dehydrogenase (IDH) in cancer.
    Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
    Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDH mutations in cancer and progress toward development of targeted therapeutics.
    Dang L; Yen K; Attar EC
    Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate.
    Balss J; Pusch S; Beck AC; Herold-Mende C; Krämer A; Thiede C; Buckel W; Langhans CD; Okun JG; von Deimling A
    Acta Neuropathol; 2012 Dec; 124(6):883-91. PubMed ID: 23117877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.
    Ward PS; Lu C; Cross JR; Abdel-Wahab O; Levine RL; Schwartz GK; Thompson CB
    J Biol Chem; 2013 Feb; 288(6):3804-15. PubMed ID: 23264629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimally Invasive Detection of IDH1 Mutation With Cell-Free Circulating Tumor DNA and D-2-Hydroxyglutarate, D/L-2-Hydroxyglutarate Ratio in Gliomas.
    Tuna G; Dal-Bekar NE; Akay A; Rükşen M; İşlekel S; İşlekel GH
    J Neuropathol Exp Neurol; 2022 Jun; 81(7):502-510. PubMed ID: 35582888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue 2-Hydroxyglutarate as a Biomarker for
    Sim HW; Nejad R; Zhang W; Nassiri F; Mason W; Aldape KD; Zadeh G; Chen EX
    Clin Cancer Res; 2019 Jun; 25(11):3366-3373. PubMed ID: 30777876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.